EP2210607A1 — N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperidin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
Assigned to Exelixis Inc · Expires 2010-07-28 · 16y expired
What this patent protects
The present invention provides a compound which is represented by the following structure: which inhibits, regulates and/or modulates kinase receptors, particularly c-Met, KDR, c-Kit, flt-3 and flt-4. This compound is therefore suitable for the treatment of diseases or diso…
USPTO Abstract
The present invention provides a compound which is represented by the following structure: which inhibits, regulates and/or modulates kinase receptors, particularly c-Met, KDR, c-Kit, flt-3 and flt-4. This compound is therefore suitable for the treatment of diseases or disorders associated with uncontrolled, abnormal and/or unwanted cellular activities.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.